About this opportunity:
The Vice President, Revenue Cycle Management will build, lead and oversee all aspects of revenue cycle operations, ensuring compliance, efficiency, and strategic optimization of patient intake, financial counseling, billing, collections, reimbursement, and financial workflows. This executive will design and implement scalable, AI-enabled automated revenue cycle infrastructure in partnership with Sales, Market Access, and Commercial Operations to maximize revenue capture, minimize denials, and enhance patient financial experience. This is a remote role with up to 25% travel.
This position reports to the Chief Financial Officer (CFO).
What you’ll do:
Must haves:
Benefits and additional information:
The US target range of our base salary for new hires is $261,725 - $337,838 You will also be eligible to receive equity, cash bonuses, and a full range of medical, financial, and other benefits depending on the position offered. Please note that individual total compensation for this position will be determined at the Company’s sole discretion and may vary based on several factors, including but not limited to, location, skill level, years and depth of relevant experience, and education. We invite you to check out our career page @ freenome.com/job-openings/ for additional company information.
Freenome is proud to be an equal-opportunity employer, and we value diversity. Freenome does not discriminate on the basis of race, color, religion, marital status, age, national origin, ancestry, physical or mental disability, medical condition, pregnancy, genetic information, gender, sexual orientation, gender identity or expression, veteran status, or any other status protected under federal, state, or local law.
Applicants have rights under Federal Employment Laws.
#LI-REMOTE

Freenome is a high-growth biotech company on a mission since 2014 to create tools that empower everyone to prevent, detect, and treat their disease.
To achieve this mission, Freenome is developing next-generation blood tests to detect cancer in its earliest, most treatable stages using our multiomics platform and machine learning techniques. Our first blood test will detect early-stage colorectal cancer and advanced adenomas.
We have raised more than $1.1 billion from leading investors like Perceptive Advisors, RA Capital Management, Roche Venture Fund, Kaiser Permanente, Novartis and the American Cancer Society’s BrightEdge Ventures.
A ‘Freenomer’ is a mission-driven employee who is fueled by the opportunity to make a positive impact on patients' lives, who thrives in a culture of respect and cross collaboration, and whose work makes a significant impact on the company and their career.